Binimetinib

• Tablets 15mg

Notes

1. NICE TA562: Encorafenib (Braftovi) with binimetinib (Mektovi) is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in adults. It is recommended only if the company provides encorafenib and binimetinib according to the commercial arrangements (February 2019)

Selumetinib

• Capsules 10mg, 25mg

Notes

1. NICE HST20: Selumetinib (Koselugo) is recommended, within its marketing authorisation, for treating symptomatic and inoperable plexiform neurofibromas (PN) associated with type 1 neurofibromatosis (NF1) in children aged 3 and over, only if the company provides selumetinib according to the commercial arrangement (May 2022)

Trametinib

• Tablets 2mg

Notes

1. NICE TA396: Trametinib (Mekinist) in combination with dabrafenib (Tafinlar) is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation only when the company provides trametinib and dabrafenib with the discounts agreed in the patient access schemes (June 2016)
2. NICE TA544: Dabrafenib (Trafinlar) with Trametinib (Mekinst) is recommended, within its marketing authorisation, as an option for the adjuvant treatment of resected stage III, BRAF V600 mutation-positive melanoma in adults. It is recommended only if the company provides dabrafenib and trametinib with the discounts agreed in the commercial arrangements (October 2018)
3. MHRA Drug Safety Update (March 2016): Trametinib (Mekinist): risk of gastrointestinal perforation and colitis

Cobimetinib

• NICE TA414: Cobimetinib (Cotellic) in combination with vemurafenib is not recommended within its marketing authorisation for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation (October 2016)